ReviewAdvances in therapy2019
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).
Review in Advances in therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 4 syntheses or guidelines pooled it, 117 citations in OpenAlex.
- Comparative efficacy and safety of first-line neoadjuvant therapy for early-stage non-small cell lung cancer based on immune checkpoint inhibitor therapy: a systematic review and network meta-analysis.BMC pulmonary medicine · 2025Pooled it
- AI models for the identification of prognostic and predictive biomarkers in lung cancer: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis.Frontiers in immunology · 2023Pooled it
- Pooled it
- Smoking Status and Survival in Patients With Early-Stage Primary Cutaneous Melanoma.JAMA network open · 2024Trial
- Automatic framework for PD-L1 expression evaluation in Latino patients with non-small cell lung cancer.Journal of pathology informatics · 2026Article
- Pharmacogenomics in oncology: mutation-targeted therapy and biomarker integration in non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- PD-1/PD-L1 expression and predictive value of efficacy in hepatocellular carcinoma patients with anti-PD-1 therapy: a real-world study.Journal of gastrointestinal oncology · 2026Article
- Inflammatory-Molecular Clusters as Predictors of Immunotherapy Response in Advanced Non-Small-Cell Lung Cancer.Journal of clinical medicine · 2026Article
- Integrative radiomics and habitat imaging models for predicting PD-L1 expression in non-small cell lung cancer.Frontiers in oncology · 2026Article
- Clinical relevance of AI-based PD-L1 scoring in non-small cell lung cancer.Frontiers in oncology · 2026Article
- Overcoming resistance mechanisms in cancer immunotherapy-novel approaches and combinations.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Predicability of PD-L1 expression in cancer cells based solely on H&E-stained sections.Journal of pathology informatics · 2025Review
- Immune-based cancer therapies: mechanistic insights, clinical progress, and future directions.Journal of the Egyptian National Cancer Institute · 2025Review
- A Comprehensive Oncological Biomarker Framework Guiding Precision Medicine.Biomolecules · 2025Review
- PD-L1 Expression and Comprehensive Genomic Profiling in Advanced NSCLC: A Single-Centre Experience.International journal of molecular sciences · 2025Article
- Potentiating the effect of immunotherapy in pancreatic cancer using gas-entrapping materials.Biomaterials · 2025Article
- Immune Checkpoint Inhibitor Score Predicts Survival Benefit of Immunotherapy in Patients with Non-small Cell Lung Cancer.Tuberculosis and respiratory diseases · 2024Article
- Identification and Application of Emerging Biomarkers in Treatment of Non-Small-Cell Lung Cancer: Systematic Review.Cancers · 2024Review
- Exploring the predictive potential of programmed death ligand 1 expression in healthy organs and lymph nodes as measured byJournal for immunotherapy of cancer · 2024Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, immunotherapy has been shown to be an effective and helpful therapeutic option for the treatment of advanced non-small-cell lung cancer (NSCLC). The activity of antitumor T cells may be restored through the checkpoint blockade using anti-programmed death 1 or anti-programmed death ligand 1 (PD-L1) antibodies, showing, in several cancer patients, an increased progression-free survival and overall survival compared with classical chemotherapy. As recently shown by several studies, the PD-L1 expression levels in tumors may offer a selection criterion for patients to predict their immunotherapy response. In particular, NSCLC patients with high tumor PD-L1 levels (proportional score ≥ 50% for first-line therapy and ≥ 1% for second-line treatment, respectively) showed better response rates to immunotherapy and longer survival in first-line therapy compared with conventional chemotherapy. PD-L1, whose expression is evaluated by using immunohistochemistry analysis, is currently the only biomarker approved for clinical use in the first- and second-line monotherapy setting and therefore plays a central role in treatment decision-making for patients with advanced NSCLC. In this review we will discuss the key role of PD-L1 as a predictive biomarker of response to pembrolizumab therapy in NSCLC patients by describing the appropriate techniques and methodologies for immunohistochemical evaluation of PD-L1 expression and providing an overview of the clinical studies supporting its predictive significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.